Clinical Trials List
2023-10-01 - 2031-12-31
Phase III
Recruiting7
ICD-10C61
Malignant neoplasm of prostate
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9185
Malignant neoplasm of prostate
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
Co-Principal Investigator
- Sheng-Chen Wen 無
- 張顥瀚 無
- Hsiang Ying Lee 無
- 盧嘉文 無
- Ching-Chia Li 無
- Hung-Lung Ke 無
- Tsu-Ming Chien 無
- 阮雍順 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Rita cheng 無
- I-hung Shao 無
- Yung-Chang Lin 無
- Jing-Ren Tseng 無
- Kai-Jie Yu 無
- 黃亮鋼 無
- Po-Jung Su 無
- 陳東藝 無
- PO-HUNG LIN 無
- Chun-Te Wu 無
- 張境夫 無
- Hong-Cheng Gan 無
- 黃文冠 無
- 張鈞弼 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chao-Hsiang Chang 無
- Po-Jen Hsiao 無
- 賴俊佑 無
- 謝德鈞 無
- Po-Fan Hsieh 無
- 邱鴻傑 無
- Chi-Shun Lien 無
- Hsi-Chin Wu 無
- 陳冠亨 無
- Yu-De Wang 無
- Han Chang 無
- Chi-Rei Yang 無
- Yi-Huei Chang 無
- 蔡禮賢 無
- Wei-Ching Lin 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
70 participants
-
Global
1800 participants
